{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T04:01:38Z","timestamp":1777003298205,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,3,17]],"date-time":"2014-03-17T00:00:00Z","timestamp":1395014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,3,17]],"date-time":"2014-03-17T00:00:00Z","timestamp":1395014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2015,2,12]]},"DOI":"10.1038\/onc.2014.17","type":"journal-article","created":{"date-parts":[[2014,3,17]],"date-time":"2014-03-17T12:01:48Z","timestamp":1395057708000},"page":"922-931","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Renal tumours in a Tsc2+\/\u2212 mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin"],"prefix":"10.1038","volume":"34","author":[{"given":"J","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Kalogerou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P A","family":"Samsel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D F R","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Gallacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J R","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M H","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,17]]},"reference":[{"key":"BFonc201417_CR1","doi-asserted-by":"publisher","first-page":"951724","DOI":"10.1155\/2012\/951724","volume":"2012","author":"N Xu","year":"2012","unstructured":"Xu N, Lao Y, Zhang Y, Gillespie DA . Akt: a double-edged sword in cell proliferation and genome stability. J Oncol 2012; 2012: 951724.","journal-title":"J Oncol"},{"key":"BFonc201417_CR2","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1042\/BST0390431","volume":"39","author":"CG Proud","year":"2011","unstructured":"Proud CG . mTOR signalling in health and disease. Biochem Soc Trans 2011; 39: 431\u2013436.","journal-title":"Biochem Soc Trans"},{"key":"BFonc201417_CR3","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1242\/dev.058230","volume":"138","author":"RC Russell","year":"2011","unstructured":"Russell RC, Fang C, Guan KL . An emerging role for TOR signalling in mammalian tissue and stem cell physiology. Development 2011; 138: 3343\u20133356.","journal-title":"Development"},{"key":"BFonc201417_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/sj.cdd.4400978","volume":"9","author":"M Castedo","year":"2002","unstructured":"Castedo M, Ferri KF, Kroemer G . Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic. Cell Death Differ 2002; 9: 99\u2013100.","journal-title":"Cell Death Differ"},{"key":"BFonc201417_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/nature04869","volume":"441","author":"RJ Shaw","year":"2006","unstructured":"Shaw RJ, Ras Cantley LC . PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441: 424\u2013430.","journal-title":"Nature"},{"key":"BFonc201417_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","volume":"12","author":"DA Guertin","year":"2007","unstructured":"Guertin DA, Sabatini DM . Defining the role of mTOR in cancer. Cancer Cell 2007; 12: 9\u201322.","journal-title":"Cancer Cell"},{"key":"BFonc201417_CR7","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.ceb.2011.09.003","volume":"23","author":"E Dazert","year":"2011","unstructured":"Dazert E, Hall MN . mTOR signalling in disease. Curr Opin Cell Biol 2011; 23: 744\u2013755.","journal-title":"Curr Opin Cell Biol"},{"key":"BFonc201417_CR8","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nrm3330","volume":"13","author":"MS Song","year":"2012","unstructured":"Song MS, Salmena L, Pandolfi PP . The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012; 13: 283\u2013296.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFonc201417_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2004.06.007","volume":"6","author":"RJ Shaw","year":"2004","unstructured":"Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA et al. The LKB1 tumor suppressor negatively regulates mTOR signalling. Cancer Cell 2004; 6: 91\u201399.","journal-title":"Cancer Cell"},{"key":"BFonc201417_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cub.2007.11.066","volume":"18","author":"CM Johannessen","year":"2008","unstructured":"Johannessen CM, Johnson BW, Williams SM, Chan AW, Reczek EE, Lynch RC et al. TORC1 is essential for NF1-associated malignancies. Curr Biol 2008; 18: 56\u201362.","journal-title":"Curr Biol"},{"key":"BFonc201417_CR11","doi-asserted-by":"publisher","first-page":"18722","DOI":"10.1073\/pnas.0908853106","volume":"106","author":"Y Hasumi","year":"2009","unstructured":"Hasumi Y, Baba M, Ajima R, Hasumi H, Valera VA, Klein ME et al. Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc Natl Acad Sci USA 2009; 106: 18722\u201318727.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc201417_CR12","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1126\/science.277.5327.805","volume":"277","author":"M van Slegtenhorst","year":"1997","unstructured":"van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997; 277: 805\u2013808.","journal-title":"Science"},{"key":"BFonc201417_CR13","doi-asserted-by":"crossref","unstructured":"European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993; 75: 1305\u20131315.","DOI":"10.1016\/0092-8674(93)90618-Z"},{"key":"BFonc201417_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1083\/jcb.jcb.200206108","volume":"159","author":"A Jaeschke","year":"2002","unstructured":"Jaeschke A, Hartkamp J, Saitoh M, Roworth W, Nobukuni T, Hodges A et al. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J Cell Biol 2002; 159: 217\u2013224.","journal-title":"J Cell Biol"},{"key":"BFonc201417_CR15","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/hmg\/11.5.525","volume":"11","author":"DJ Kwiatkowski","year":"2002","unstructured":"Kwiatkowski DJ, Zhang H, Bandura JL, Heiberger KM, Glogauer M, el-Hashemite N et al. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet 2002; 11: 525\u2013534.","journal-title":"Hum Mol Genet"},{"key":"BFonc201417_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1083\/jcb.200403069","volume":"166","author":"LS Harrington","year":"2004","unstructured":"Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H et al. The TSC1-2 tumor suppressor controls insulin-PI3K signalling via regulation of IRS proteins. J Cell Biol 2004; 166: 213\u2013223.","journal-title":"J Cell Biol"},{"key":"BFonc201417_CR17","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.cub.2004.08.026","volume":"14","author":"OJ Shah","year":"2004","unstructured":"Shah OJ, Wang Z, Hunter T . Inappropriate activation of the TSC\/Rheb\/mTOR\/S6K cassette induces IRS1\/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 2004; 14: 1650\u20131656.","journal-title":"Curr Biol"},{"key":"BFonc201417_CR18","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1126\/science.1199484","volume":"332","author":"Y Yu","year":"2011","unstructured":"Yu Y, Yoon SO, Poulogiannis G, Yang Q, Ma XM, Vill\u00e9n J et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signalling. Science 2011; 332: 1322\u20131326.","journal-title":"Science"},{"key":"BFonc201417_CR19","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1126\/science.1199498","volume":"332","author":"PP Hsu","year":"2011","unstructured":"Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signalling. Science 2011; 332: 1317\u20131322.","journal-title":"Science"},{"key":"BFonc201417_CR20","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1172\/JCI28984","volume":"117","author":"H Zhang","year":"2007","unstructured":"Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, Dabora SL et al. PDGFRs are critical for PI3K\/Akt activation and negatively regulated by mTOR. J Clin Invest 2007; 117: 730\u2013738.","journal-title":"J Clin Invest"},{"key":"BFonc201417_CR21","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1101\/gad.1314605","volume":"19","author":"BD Manning","year":"2005","unstructured":"Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ, Cantley LC . Feedback inhibition of Akt signalling limits the growth of tumors lacking Tsc2. Genes Dev 2005; 19: 1773\u20131778.","journal-title":"Genes Dev"},{"key":"BFonc201417_CR22","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI7319","volume":"104","author":"H Onda","year":"1999","unstructured":"Onda H, Lueck A, Marks PW, Warren HB, Kwiatkowski DJ . Tsc2(+\/\u2212) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J Clin Invest 1999; 104: 687\u2013695.","journal-title":"J Clin Invest"},{"key":"BFonc201417_CR23","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/hmg\/ddi190","volume":"14","author":"C Wilson","year":"2005","unstructured":"Wilson C, Idziaszczyk S, Parry L, Guy C, Griffiths DF, Lazda E et al. A mouse model of tuberous sclerosis 1 showing background specific early post-natal mortality and metastatic renal cell carcinoma. Hum Mol Genet 2005; 14: 1839\u20131850.","journal-title":"Hum Mol Genet"},{"key":"BFonc201417_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/gcc.20118","volume":"42","author":"L Lee","year":"2005","unstructured":"Lee L, Sudentas P, Donohue B, Asrican K, Worku A, Walker V et al. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer 2005; 42: 213\u2013227.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFonc201417_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1476-4598-8-38","volume":"8","author":"K Pollizzi","year":"2009","unstructured":"Pollizzi K, Malinowska-Kolodziej I, Stumm M, Lane H, Kwiatkowski D . Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis. Mol Cancer 2009; 8: 38.","journal-title":"Mol Cancer"},{"key":"BFonc201417_CR26","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa063564","volume":"358","author":"JJ Bissler","year":"2008","unstructured":"Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358: 140\u2013151.","journal-title":"N Engl J Med"},{"key":"BFonc201417_CR27","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","volume":"363","author":"DA Krueger","year":"2010","unstructured":"Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. New Engl J Med 2010; 363: 1801\u20131811.","journal-title":"New Engl J Med"},{"key":"BFonc201417_CR28","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.devcel.2006.10.007","volume":"11","author":"DA Guertin","year":"2006","unstructured":"Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signalling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 2006; 11: 859\u2013871.","journal-title":"Dev Cell"},{"key":"BFonc201417_CR29","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1038\/emboj.2008.119","volume":"27","author":"T Ikenoue","year":"2008","unstructured":"Ikenoue T, Inoki K, Yang Q, Zhou X, Guan KL . Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J 2008; 27: 1919\u20131931.","journal-title":"EMBO J"},{"key":"BFonc201417_CR30","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1016\/j.ejrad.2011.06.054","volume":"81","author":"M Kalogerou","year":"2012","unstructured":"Kalogerou M, Zhang Y, Yang J, Garrahan N, Paisey S, Tokarczuk P et al. T2 weighted MRI for assessing renal lesions in transgenic mouse models of tuberous sclerosis. Eur J Radiol 2012; 81: 2069\u20132074.","journal-title":"Eur J Radiol"},{"key":"BFonc201417_CR31","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.1158\/0008-5472.CAN-09-0975","volume":"69","author":"J Huang","year":"2009","unstructured":"Huang J, Wu S, Wu CL, Manning BD . Signaling events downstream of mammalian target of rapamycin complex2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. Cancer Res 2009; 69: 6107\u20136114.","journal-title":"Cancer Res"},{"key":"BFonc201417_CR32","first-page":"3065","volume":"118","author":"A Carracedo","year":"2008","unstructured":"Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118: 3065\u20133074.","journal-title":"J Clin Invest"},{"key":"BFonc201417_CR33","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O'Reilly","year":"2006","unstructured":"O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D et al. mTOR inhibition induces upstream receptor tyrosine kinase signalling and activates Akt. Cancer Res 2006; 66: 1500\u20131508.","journal-title":"Cancer Res"},{"key":"BFonc201417_CR34","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","volume":"26","author":"X Wan","year":"2007","unstructured":"Wan X, Harkavy B, Shen N, Grohar P, Helman LJ . Rapamycin induces feedback activation of Akt signalling through an IGF-1R-dependent mechanism. Oncogene 2007; 26: 1932\u20131940.","journal-title":"Oncogene"},{"key":"BFonc201417_CR35","doi-asserted-by":"publisher","first-page":"40758","DOI":"10.1074\/jbc.M112.405209","volume":"287","author":"X Xu","year":"2012","unstructured":"Xu X, Keshwani M, Meyer K, Sarikas A, Taylor S, Pan ZQ . Identification of the degradation determinants of insulin receptor substrate 1 for signaling cullin-RING E3 ubiquitin ligase 7-mediated ubiquitination. J Biol Chem 2012; 287: 40758\u201340766.","journal-title":"J Biol Chem"},{"key":"BFonc201417_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","volume":"22","author":"DD Sarbassov","year":"2006","unstructured":"Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB. Mol Cell 2006; 22: 159\u2013168.","journal-title":"Mol Cell"},{"key":"BFonc201417_CR37","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1126\/science.1215135","volume":"335","author":"DW Lamming","year":"2012","unstructured":"Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012; 335: 1638\u20131643.","journal-title":"Science"},{"key":"BFonc201417_CR38","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1172\/JCI200317222","volume":"112","author":"H Zhang","year":"2003","unstructured":"Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N et al. Loss of Tsc1\/Tsc2 activates mTOR and disrupts PI3K-Akt signalling through downregulation of PDGFR. J Clin Invest 2003; 112: 1223\u20131233.","journal-title":"J Clin Invest"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc201417.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc201417","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc201417.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T20:20:57Z","timestamp":1647894057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc201417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,17]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,2,12]]}},"alternative-id":["BFonc201417"],"URL":"https:\/\/doi.org\/10.1038\/onc.2014.17","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,17]]},"assertion":[{"value":"14 August 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}